(primary solid tumor cohort)
This pipeline maps genes, with mutation or copy number alteration AND this alteration is highly correlated with mRNA expression, to pathways curated in the KEGG and BIOCARTA databases. It identifies pathways significantly enriched with these genes. The pipeline also identifies pathways significantly enriched with marker genes of each expression subtype of cancer.
genes with mutation: identified by the Mutation_Significance pipeline
genes with copy number alteration: identified by the CopyNumber_Gistic2 pipeline
correlation between copy number and mRNA expression: identified by the Correlate_CopyNumber_vs_mRNA pipeline
marker genes and expression subtypes: identified by the mRNAConsensusClustering pipeline
There are 26 genes with significant mutation (Q value <= 0.1) and 171 genes with significant copy number alteration (Q value <= 0.25). The identified marker genes (Q value <= 0.01 or within top 2000) are 2000 for subtype 1, 2000 for subtype 2, 2000 for subtype 3. Pathways significantly enriched with these genes (Q value <= 0.01) are identified :
0 pathways significantly enriched with genes with copy number alteration or mutation.
0 pathways significantly enriched with marker genes of gene expression subtype 1
0 pathways significantly enriched with marker genes of gene expression subtype 2
1 pathways significantly enriched with marker genes of gene expression subtype 3
Pathway | Nof Genes | Nof CNV_Mut | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_RACCYCD_PATHWAY | 26 | 4 | 4 | 0.0001 | 0.018 |
BIOCARTA_TNFR1_PATHWAY | 29 | 4 | 3.9 | 0.0001 | 0.018 |
KEGG_CITRATE_CYCLE_TCA_CYCLE | 32 | 4 | 3.8 | 0.0002 | 0.018 |
BIOCARTA_TOLL_PATHWAY | 37 | 4 | 3.5 | 0.0004 | 0.031 |
KEGG_CHRONIC_MYELOID_LEUKEMIA | 73 | 5 | 2.9 | 0.0006 | 0.04 |
TFDP1,RB1,CDKN1B,IKBKB
MAP3K7,MAP2K4,RB1,RIPK1
PDHB,FH,DLAT,SDHD
TOLLIP,MAP3K7,MAP2K4,IKBKB
GAB2,RB1,KRAS,CDKN1B,IKBKB
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | 272 | 40 | 0.75 | 0.0005 | 0.18 |
KEGG_VIRAL_MYOCARDITIS | 73 | 13 | 1.1 | 0.0043 | 0.72 |
KEGG_PURINE_METABOLISM | 158 | 22 | 0.66 | 0.017 | 0.79 |
KEGG_RIBOSOME | 87 | 14 | 0.89 | 0.015 | 0.79 |
KEGG_SPLICEOSOME | 126 | 18 | 0.86 | 0.0097 | 0.79 |
ADORA3,S1PR1,GRIN2B,LTB4R,S1PR5,GRID1,CRHR1,CRHR2,SSTR1,F2,GPR156,GH2,CHRNB4,CHRNB2,CHRNB1,GPR83,TRPV1,EDNRB,NMUR1,RXFP2,GRM8,GRM7,GRM6,PARD3,NPY2R,FPR1,GHRHR,DRD3,ADORA2A,DRD5,GABRQ,GABRD,GABRA2,GABRA3,P2RX3,CALCRL,PTGER2,CHRM5,PTAFR,DHX8
CASP3,CASP9,MYH1,HLA-G,HLA-F,EIF4G3,SGCG,CD40LG,SGCA,CAV1,ITGB2,RAC3,ABL2
PDE3B,POLE,PDE4D,POLR2J2,POLE2,ENTPD3,PRPS1L1,ENTPD2,GUCY2C,NT5M,ADCY10,NT5E,IMPDH1,PDE10A,PKM2,GUCY1B3,POLR2E,POLR2C,PDE1B,ATIC,POLR3A,AMPD1
RPL18,RPL13,RPL22L1,RPS2,RPL26L1,RPL35A,RPS13,MRPL13,RPL30,RPL5,RPL10A,RPL26,RPS5,RPL22
SNRPD2,CTNNBL1,SFRS7,LSM4,SFRS2,AQR,SNRPE,SNRPB2,TCERG1,ISY1,DHX8,SNRNP27,BUD31,PLRG1,THOC2,THOC1,SF3B4,SF3B3
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_EIF_PATHWAY | 16 | 6 | 2.2 | 0.0011 | 0.15 |
KEGG_LYSINE_DEGRADATION | 44 | 11 | 1.5 | 0.0008 | 0.15 |
KEGG_PROTEASOME | 48 | 10 | 1.4 | 0.0037 | 0.15 |
KEGG_TGF_BETA_SIGNALING_PATHWAY | 86 | 16 | 1.1 | 0.0024 | 0.15 |
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 89 | 15 | 1.1 | 0.0029 | 0.15 |
EIF5,EIF4G3,EIF2S1,EIF4A1,EEF2K,EIF1
EHHADH,SETD1A,AASS,ACAT1,PLOD2,PLOD3,AASDH,DLST,EHMT2,SETD7,NSD1
SHFM1,PSMB11,PSMB5,PSMB3,PSMD3,PSMA1,PSMD13,PSMC4,PSMC1,POMP
FST,RHOA,MYC,LEFTY1,ACVR1,TNF,DCN,THBS3,TFDP1,TGFBR1,CREBBP,ID2,BMP7,BMP5,BMP8B,BMP8A
KLRC2,RFXAP,HLA-A,HLA-B,HLA-E,HLA-DQA2,HLA-G,HLA-F,KIR2DL4,KIR3DL2,HLA-DQB1,CALR,HSPA4,HSPA5,IFNA14
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_MAPK_SIGNALING_PATHWAY | 267 | 44 | 0.9 | 0 | 0.0037 |
KEGG_RIBOSOME | 87 | 19 | 1.3 | 0.0001 | 0.011 |
BIOCARTA_ERK_PATHWAY | 28 | 9 | 1.9 | 0.0004 | 0.011 |
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION | 115 | 22 | 1.1 | 0.0002 | 0.011 |
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY | 108 | 21 | 1.2 | 0.0003 | 0.011 |
PRKX,MAP3K7,MAPKSP1,MAPK1,JUN,PLA2G2E,PLA2G2F,TAOK1,TGFBR1,NTRK1,FGF5,FGF4,CACNG7,CACNG6,MAP3K14,MAP3K12,MKNK2,RPS6KA5,RPS6KA3,MAPK12,ZAK,FGF11,TGFB2,PRKACB,STK3,RASGRF1,FGFR4,GRB2,JUND,PTPN5,NR4A1,CACNA1S,CACNA2D4,PAK2,AKT2,PRKCG,TNF,PPP3R2,TNFRSF1A,HSPA2,RASGRP4,RAF1,MAPK8IP2,MAPK8IP3
RPL18,RPL36AL,RPL14,RPL13,RPS3,RPL26L1,FAU,RPS13,RPS11,RPL27A,RPS27,RPL30,RPL32,RPL8,RPS21,RPL23A,RPS5,RPL29,RPL21
GRB2,MKNK2,IGF1R,PPP2CA,RAF1,RPS6KA5,MAPK1,GNGT1,GNAS
ADCY8,PRKG1,PRKX,PRKACB,ROCK2,MAPK1,PPP1CA,PLA2G2E,PLA2G2F,MYL6,CACNA1S,AVPR1B,AVPR1A,GUCY1A3,KCNMA1,PRKCG,PRKCQ,GNAS,CALML6,CALML5,RAF1,CALM3
MAP3K7,MAPK1,JUN,GRB2,NFKBIA,VAV1,CD8B,PAK6,PAK2,AKT2,CARD11,PRKCQ,MAP3K14,LCP2,CSF2,TNF,PPP3R2,NFATC1,CBL,RAF1,MAPK12
Let genes with copy number alteration or mutation be query genes. Let marker genes of specific identified subtypes be query genes. The Enrichment is calculated as:
-
Enrichment = log2 (# of query genes in the pathway/# No of query genes) - log2 (# of genes in the pathway/# of human genes)
The statistical signficance of the pathways that are enriched with genes with copy number alteration or mutation, and the pathways that are enriched with markers genes of specific identified subtypes is measured by P value.
-
P value = Fisher exact P value
The Q value is for adjusting P value for multiple testing. A public available R package is used to calculate the Q value.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.